Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Looking Off-Label: Drug-Eluting Stents Versus Surgery And Bare-Metal

This article was originally published in The Gray Sheet

Executive Summary

Two registry studies reported last week assess outcomes from drug-eluting stent procedures in patients with conditions that are not approved indications for the device. In one, the stents did not match the outcomes of open-heart surgery, but in the other the devices outpeformed their bare-metal cousins

You may also be interested in...

Drug-Eluting-Stent Market Penetration At Nadir? Rebound Forecast At TCT

U.S. drug-eluting-stent market penetration reached an all-time low in September, but clinicians meeting last week in Washington, D.C., are confident new data will help to reverse the trend that began just over a year ago

Off-Label Drug-Eluting Stent Data Weak; Label Should Be Revised – Panel

FDA panel members recommended changes to drug-eluting stent labeling that would more clearly indicate differences between on- and off-label use. However, they found that the data was insufficient to make definitive conclusions about risks for unapproved applications, which account for the majority of stent placements

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts